Patent ID: 6589991
Filing Date: 2003-07-08
Classification: A61K,A61P,Y02A,Y10S

Abstract:
A method for treating a disease state associated with a nuclear factor kappa B pathway, said method comprising administering a composition to a subject in need thereof in an amount effective to inhibit a nuclear factor kappa B pathway in the subject, said composition comprising:i. a pharmaceutically acceptable carrier; ii. a compound having the structure (I) as follows: R1R2Nâ€”C(S)â€”Sâ€”Sâ€”(S)Câ€”NR2R1 â€ƒâ€ƒ(I) wherein:each of R1 and R2 is independently selected from a C1 up to C18 alkyl, substituted alkyl, a cycloalkyl, a substituted cycloalkyl, heterocyclic, a substituted heterocyclic, an alkenyl, a substituted alkenyl, an alkynyl, a substituted alkynyl, an aryl, a substituted aryl, an heteroaryl, a substituted heteroaryl, an alkylaryl, a substituted alkylaryl, an arylalkyl, and a substituted arylalkyl, or wherein R1 and R2 cooperate to form a 5-, 6- or 7-membered ring including N, R1 and R2 or R1 or R2 is a divalent moiety selected from the group consisting of an alkylene, a substituted alkylene, an oxyalkylene, a substituted oxyalkylene, an alkenylene, a substituted alkenylene, an arylene, a substituted arylene, an alkarylene, a substituted alkarylene, an aralkylene and a substituted aralkylene, wherein said divalent moiety serves as the same substituted for two dithiocarbamate structures, thereby linking said structures together so as to form a bis(dithiocarbamate), and iii. optionally, a biocompatible reducing agent to reduce the disulfide bond in the dithiocarbamate.